FUNDING
Medical device and diagnostics companies are always looking for ways to improve their products and services. In the ever-changing landscape of the healthcare industry, it’s essential for these companies to stay ahead of the curve. That’s why funding is always news.
Series A, B, and other rounds of funding are essential for medical device and diagnostics companies. They provide the necessary capital to help these businesses grow and innovate. And with so many investors interested in this space, there are plenty of opportunities for companies to secure the funding they need.
InterShunt Technologies Announces Equity Financing
Funding will be used to support the research and development of the Percutaneous Atrial Shunt Catheter System.
Neuros Medical Raises $38.5M in Series BB: Funds Enable Completion of Pivotal Clinical Study for Chronic Post-Amputation Pain
The financing provides capital to complete enrollment of the pivotal QUEST (High-FreQUEncy Nerve Block for PoST-Amputation Pain) study, and to submit an anticipated application for Pre-Market Approval. QUEST is a 180-subject, randomized, double-blinded, active sham-controlled clinical trial that is being conducted under an Investigational Device Exemption
Volta Medical Raises $28 Million: To Establish its FDA-cleared and CE marked VX1 AI Software Solution As a New Standard of Care
Volta Medical advises that the financing round was led by Gilde Healthcare with the participation of existing shareholder Pasteur Mutualité.
Emboline Raises Over $10 Million in Series C Funding: Funds Raised To Be Used to Obtain Initial Commercial Approval of the Emboliner & Launch...
xEmboline recently completed the 3-center, 31-patient SafePass 2 study of the Emboliner™ in New Zealand in which the device met all primary endpoints for safety and technical performance when used during TAVR.
Fujifilm to invest $40 Million to Establish a New State-of-the-Art Viral Vector and Advanced Therapy Process Development and Manufacturing Facility
Fujifilm notes the new facility is scheduled to begin process development operations in fall 2021.
Ensysce Biosciences Secures $60 Million Capital Commitment From Global Emerging Markets
Ensyce Biosciences notes under the accord, GEM agrees to provide Ensysce with a share subscription facility of up to $60 million for a 36-month term following the public listing of the Company's common stock.
AIVITA Biomedical Successfully Closes $25 Million Financing Round: Funds Support Ongoing Development of Personalized COVID-19 Prevention Vaccine
The roceeds will support clinical development of AIVITA's personalized immunotherapy programs.
Coagulo Medical Technologies Raises $6.5 Million in Financing: To Accelerate Delivery of Disruptive Coagulation Diagnostics Platform
The company also announced that it has been awarded a Small Business Innovation Research (SBIR) grant by the National Science Foundation to accelerate delivery of breakthrough innovations amid the global COVID–19 public health crisis, which has called attention to the limitations of conventional coagulation tests.
Atriomx Health Announces $10 Million Series A Financing-Funds to Be Used for Development and Clinical Study
"This financing will allow Atriomx to pursue the tremendous opportunity to transform the diagnosis and treatment of atrial fibrillation stemming from the application of novel AF detection and characterization capabilities to data that can be collected non-invasively," said Duke Rohlen, CEO of Ajax Health and Zeus Health.
Medical Device News Magazine